NEW YORK (GenomeWeb) – Molecular diagnostics firm Invitae said on Monday after the close of the market that it is acquiring Good Start Genetics and CombiMatrix.

Separately, the company announced it would sell $73.5 million of its stock in a private placement and announced preliminary financial results for the second quarter. 

To read the full story....

Register for Free.

Already have a GenomeWeb or 360Dx account?
Login Now.

An opinion piece in the Guardian argues that President Donald Trump is uninterested in science and that might not be a bad thing for the field.

The San Francisco Chronicle reports the Veterans Affairs Health System is studying whether genetic testing can help prescribe better depression therapies.

Stat News reports that Spark Therapeutics' Luxturna is now being used to treat a wider array of patients.

In Genome Biology this week: transcription factor use among brittle stars, single-cell RNA sequencing strategy, and more.